Takeda

CompanyJapanFounded 1781

ROROpenAlexWikidata

Takeda develops 55 assets, the furthest approved (Actos in type 2 diabetes). Mostly small molecule and protein or enzyme acting on DPP4, AGTR1 and PPARG; based in Japan, founded in 1781.

55
Assets
Furthest stage
Approved
627
Trials
535
Signals

Pipeline

55
  • Actos

    PPAR-gamma agonist improving insulin sensitivity and glycemic control.

    Approved, Small molecule, PPARG, type 2 diabetes, diabetes mellitus (Phase 3)

  • Alogliptin

    Inhibits DPP-4, increasing incretin activity to enhance glucose-dependent insulin secretion and reduce glucagon secretion.

    Approved, Small molecule, DPP4, type 2 diabetes, diabetes mellitus (Phase 3)

  • Alogliptin and Metformin Fixed-Dose Combination

    Fixed-dose combination of DPP-4 inhibitor alogliptin and biguanide metformin.

    Approved, Small molecule, type 2 diabetes, diabetes mellitus (Phase 3)

52 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

7

In the full profile

  • Evidence behind the mechanisms10
  • Trials972
  • Deals7
  • Signals20
  • Integrity notices2
  • Similar companies6

Papers

Intelligence